EUCTR2011-000749-19-DK进行中（未招募）不适用
eukaemia Lymphoma Research and NCRI Working Group Pick a Winner Programme (LI-1) Trial - LI-1
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 1,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients are eligible for the LI-1 trial if:
- •They have one of the forms of acute myeloid leukaemia, except Acute Promyelocytic Leukaemia as defined by the WHO Classification (Appendix A) this can be any type of de novo or secondary AML – or high risk Myelodysplastic Syndrome, defined as greater than 10% marrow blasts (RAEB-2).
- •Note: patients with prior MDS who have received azacitidine may enter the trial only if they have progressed to AML
- •They should be over the age of 60
- •They have given written informed consent.
- •Male patients with partners of childbearing potential must agree to use effective contraception during the study period and a period of 3 months after the last dose of study drug.
- •Please note for the AC220 (quizartinib) and ganetespib interventions:
- •Additional cardiac criteria must be met
- •Electrolyte levels of Potassium, Magnesium and Calcium must be within the institutional normal range
- •Male patients must also use effective contraception
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 100
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 900
排除标准
- •Patients are not eligible for the LI-1 trial if:
- •They are less than 60 years of age
- •They have previously received cytotoxic chemotherapy for AML. [Hydroxycarbamide, or similar low-dose therapy, to control the white count is not an exclusion criterion].
- •They are in blast transformation of chronic myeloid leukaemia (CML).
- •They have a concurrent active malignancy under treatment.
- •They are pregnant or lactating.
- •They have Acute Promyelocytic Leukaemia.
- •Known infection with human immunodeficiency virus (HIV)
- •Total bilirubin = 1.5 x ULN, unless due to Gilbert’s syndrome
- •Aspartate aminotransferase (AST) = 2.5 x ULN and/or alkaline phosphatase =2.5 x ULN
- •Serum creatinine = 175µmol/L
- •History of myocardial infarction (MI), unstable angina, cerebrovascular accident, or transient ischemic attack (CVA/TIA) within 6 months
- •For AC220 (quizartinib) and ganetespib treatment the following criteria make a patient ineligible for that randomisation:
- •A myocardial infarction within 12 months
- •Uncontrolled angina within 6 months
- •Current or history of congestive heart failure New York Heart Association (NYHA) class 3 or 4, unless an echocardiogram (ECHO) or Multiple Gated Acquisition Scan (MUGA) performed either within 1 month prior to study screening or during screening results in a left ventricular ejection fraction (LVEF) that is = 45% (or institutional lower limit of normal value).
- •Diagnosed or suspected congenital long QT syndrome. Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, torsades de pointes [TdP]) or any history of arrhythmia will be discussed with the Clinical Coordinator/Safety Physician prior to patient’s entry into the study.
- •Prolonged QTcF interval on pre-entry ECG (=450 ms)
- •Any history of second or third degree heart block (may be eligible if the patient currently has a pacemaker
- •Heart rate < 50/minute on pre-entry ECG
- •Uncontrolled hypertension
- •Obligate need for a cardiac pacemaker
- •Complete left bundle branch block
- •Uncontrolled atrial fibrillation
研究者
相似试验
已完成
2 期
eukaemia Lymphoma Research and NCRI Working Group Pick a Winner Programme (LI-1) TrialCancerISRCTN40571019Cardiff University (UK)243
已完成
不适用
Medical Research Council Acute Lymphoblastic Leukaemia Trial in Children UKALL R1eukaemia (acute)CancerLeukaemiaISRCTN13327255Medical Research Council (MRC) (UK)256
已完成
不适用
Medical Research Council Adult Acute Lymphoblastic Leukaemia Trial UKALL XAeukaemia (acute)Lymphoid leukaemiaCancerISRCTN35362654Medical Research Council (MRC) (UK)618
进行中（未招募）
不适用
AML19 PilotEUCTR2013-000501-22-GBCardiff Univeristy153
尚未招募
不适用
Exploratory clinical study of lymphatic and blood flow evaluation by indocyanine-green fluorescence imaging in esophageal cancer operatioEsophageal cancer patient whose assigned to surgical treatmentJPRN-UMIN000030165niversity of Tokyo Hospital19